Attached files

file filename
EX-32.2 - EX-32.2 - Horizon Therapeutics Public Ltd Cohznp-ex322_549.htm
EX-31.2 - EX-31.2 - Horizon Therapeutics Public Ltd Cohznp-ex312_551.htm
EX-31.1 - EX-31.1 - Horizon Therapeutics Public Ltd Cohznp-ex311_552.htm
EX-10.4 - EX-10.4 - Horizon Therapeutics Public Ltd Coex104.htm
EX-10.3 - EX-10.3 - Horizon Therapeutics Public Ltd Coex103.htm
EX-10.2 - EX-10.2 - Horizon Therapeutics Public Ltd Coex102.htm
EX-10.1 - EX-10.1 - Horizon Therapeutics Public Ltd Coex101.htm
10-Q - 10-Q - Horizon Therapeutics Public Ltd Cohznp-10q_20200930.htm

 

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), I, Timothy Walbert, President, Chief Executive Officer and Chairman of the Board of Horizon Therapeutics PLC (the “Company”), certify to the best of my knowledge that:

 

1.

the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2020 (the “Report”), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

 

2.

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 2, 2020

 

/s/ Timothy Walbert

 

 

Timothy Walbert

 

 

Chairman, President and Chief Executive Officer

 

 

(Principal Executive Officer)

 

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.